Journal
BLOOD
Volume 112, Issue 13, Pages 4808-4817Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-07-077958
Keywords
-
Categories
Funding
- National Cancer Institute
- The Leukemia & Lymphoma Society
- Burroughs Wellcome Fund
- T. J. Martell Foundation
- Doris Duke Charitable Foundation
- Howard Hughes Medical Institute
Ask authors/readers for more resources
Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy. These range from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease. The successful development of imatinib as a therapeutic agent for CML can be attributed directly to decades of scientific discoveries. These discoveries determined that the BCR-ABL tyrosine kinase is the critical pathogenetic event in CML and an ideal target for therapy. This was confirmed in clinical trials of imatinib, with imatinib significantly improving the long-term survival of patients with CML. Continuing in this tradition of scientific discoveries leading to improved therapies, the understanding of resistance to imatinib has rapidly led to strategies to circumvent resistance. Continued studies of hematologic malignancies will allow this paradigm of targeting molecular pathogenetic events to be applied to many additional hematologic cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available